Don Morel: Thank you very much, Bill. This concludes our prepared remarks this morning and we now look forward to answering your questions. Operator.
Don Morel: Yes. In PPS, it’s about $336 million. Overall, it’s about $353 million. We’ve got a bit of an unusual circumstance in the quarter and that the part of the PPS backlog will be pushed into the second quarter. And that simply inventory management by two key customers that have pushed some orders out. We also had one unique item where a process change resulted in a fairly large customer in the high value product line actually ordering more than they would normally order to accommodate line trials to prove out the process change. So in fact what you got is a slightly higher percentage of the existing backlog actually being three to six months out instead of just three months out.
Don Morel: I would not comment on that because of our confidentiality agreement with the customer and the timing of the trial is fully up to the design and the enrolment by the customer. Our best bet right now is second quarter it may slip into the third quarter. I think the important thing is that we began shipping clinical units from operations for that trial.
Don Morel: There is a lot of categories that could have a dramatic impact on SmartDose. So I think what’s encouraging for us is I said in my prepared remarks is that we have two other development agreements that we entered into in the fourth quarter, certainly if you talk to the industry, the opportunity to formulate differently is going to I think bring patch injectors of this type to the forefront over the next three to five years especially if some of these new therapies come to market. So we think we are in a good space. We like the combination of our technology with the CZ containment system. We think it’s a unique offering and hopefully we will be able to provide some more color as things unfold through the year.
Don Morel: Sure. Let me start with the contract and CZ contribution and Bill can comment on the packaging side. Contract manufacturing should actually have a pretty good year. We are seeing the two programs that were delayed last year coming into full production sometime by probably the middle part of the second or later part of the second quarter. So we are very encouraged by that. We have another program we expect to be substantial coming in the second half of the year. So if volumes hold steady, we think that that will be a good contributor. CZ is going to be a bit lumpy as we talked about before, it’s difficult to predict based on demands for clinical trials and line validation. We would certainly expect revenues to be on par with this year or above. So we are looking forward to good performance in both of those areas.
Don Morel: Nothing, it really stands out. The biggest issue was one of the major manufacturers announced that they were going to seize production last year. We expect that volume to go to other producers. It just hasn’t shown up in our forecast yet.
Don Morel: On the revenue side, I think we are comfortable with that. This is the reason we guide the years, okay, every once in a while we get shift in order patterns that are difficult to predict. We are very confident in the full year number and we will see how the order book fills out for Q1 and talk about that when we get our call in April.
Don Morel: Yes, two years is the best rule of thumb. We should also add a safety factor in, because remember they are going to have to run line trials to get the plastic into their operations as well. So, two years is a pretty good figure on the formal stability.
Don Morel: Well, what we see generally is we try to put a band around it for you. Now, 125 to 145 is a good proxy for what we see over time. The mission really comes down to what is in the composition of that 125 to 145. Clearly, there is an amount of normal maintenance capital. So, our capital intensive business it is about $65 million growing as the portfolio of underlying assets grows. We spend about $10 million to $15 million per year on IT as we upgrade systems and infrastructure. We will spend as we said in the prepared remarks somewhere in the $20 million this year relative to China and India probably a similar amount next year and perhaps even into 2016 a little bit, but then that will falloff. But at the same time, we will be continuing to put additional capacity into our high value product offerings on the component side of the business. So for instance, vision system, additions to those existing lines, infection lines, as well as clean ones to bag off the products in a clean environment, all this represents a push by not only the regulators, but our customers to go to as a higher quality cleaner product. All of those things will factor into our CapEx as we go. And on the Delivery Systems’ side, there is a little bit of maintenance as it relates to the contract manufacturing business, but the bulk of that spend over on that side of the business will be for the increased capacity relative to CZ, SmartDose and the other proprietary products.
Don Morel: Thank you very much operator and thank you everyone for your time this morning. We look forward to updating you on the year when we come to our first quarter conference call in late April. Thank you very much.
